INTERVENTION 1:	Intervention	0
Docetaxel	Intervention	1
3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)	Intervention	2
f	UO:0000195	10-11
f	UO:0000195	12-13
f	UO:0000195	20-21
f	UO:0000195	76-77
f	UO:0000195	98-99
Cyclophosphamide: 500 mg/m² every 3 weeks Docetaxel: 100 mg/m² every 3 weeks Epirubicin hydrochloride: 100 mg/m² every 3 weeks Fluorouracil: 500 mg/m² every 3 weeks	Intervention	3
cyclophosphamide	CHEBI:4026	0-16
hydrochloride	CHEBI:36807	88-101
INTERVENTION 2:	Intervention	4
Ixabepilone	Intervention	5
ixabepilone	CHEBI:63605	0-11
3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);	Intervention	6
f	UO:0000195	10-11
f	UO:0000195	12-13
f	UO:0000195	20-21
f	UO:0000195	76-77
f	UO:0000195	98-99
ixabepilone	CHEBI:63605	100-111
Cyclophosphamide: 500 mg/m² every 3 weeks Epirubicin hydrochloride: 100 mg/m² every 3 weeks Fluorouracil: 500 mg/m² every 3 weeks Ixabepilone: 40 mg/m² every 3 weeks	Intervention	7
cyclophosphamide	CHEBI:4026	0-16
hydrochloride	CHEBI:36807	53-66
ixabepilone	CHEBI:63605	130-141
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Inclusion criteria:	Eligibility	1
Histologically proven invasive unilateral breast cancer (regardless of the type)	Eligibility	2
unilateral	HP:0012833	31-41
breast cancer	DOID:1612	42-55
Initial clinical condition compatible with complete initial resection	Eligibility	3
condition	PDRO:0000129	17-26
No residual macro or microscopic tumor after surgical excision	Eligibility	4
Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :	Eligibility	5
disease	DOID:4,OGMS:0000031	14-21
disease	DOID:4,OGMS:0000031	106-113
Stage II or III disease	Eligibility	6
disease	DOID:4,OGMS:0000031	16-23
pT >20 mm (T1-4)	Eligibility	7
Patients must meet 1 of the following hormone-receptor criteria:	Eligibility	8
Node-positive patients: triple-negative* tumor (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+)	Eligibility	9
progesterone	CHEBI:17026	100-112
receptor	BAO:0000281	72-80
receptor	BAO:0000281	113-121
Node-negative patients: triple-negative* tumor only	Eligibility	10
NOTE: *Hormone-receptor negativity is defined as ER <10% and PR <10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative	Eligibility	11
Must be able to begin chemotherapy no later than day 49 after the initial surgery	Eligibility	12
day	UO:0000033	49-52
surgery	OAE:0000067	74-81
Exclusion criteria:	Eligibility	13
Clinically or radiologically detectable metastases (M0)	Eligibility	14
Bilateral breast cancer or contralateral ductal carcinoma in situ	Eligibility	15
bilateral breast cancer	DOID:6741	0-23
ductal carcinoma in situ	HP:0030075,DOID:0060074	41-65
Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type	Eligibility	16
Any tumor T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)	Eligibility	17
breast cancer	DOID:1612	64-77
HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive	Eligibility	18
Any clinically or radiologically suspect and non-explored damage to the contralateral breast	Eligibility	19
breast	UBERON:0000310	86-92
PATIENT CHARACTERISTICS:	Eligibility	20
patient	HADO:0000008,OAE:0001817	0-7
Inclusion criteria:	Eligibility	21
Female	Eligibility	22
female	PATO:0000383	0-6
Pre- or postmenopausal	Eligibility	23
ECOG performance status 0-1	Eligibility	24
Peripheral neuropathy grade 1	Eligibility	25
peripheral neuropathy	HP:0009830,DOID:870	0-21
Neutrophil count 2,000/mm³	Eligibility	26
Platelet count 100,000/mm³	Eligibility	27
platelet count	CMO:0000029	0-14
Hemoglobin >9 g/dL	Eligibility	28
hemoglobin	CHEBI:35143	0-10
AST and ALT 1.5 times upper limit of normal (ULN)	Eligibility	29
Alkaline phosphatase 2.5 times ULN	Eligibility	30
phosphatase	GO:0016791,BAO:0000295	9-20
Total bilirubin 1.0 times ULN	Eligibility	31
Serum creatinine 1.5 times ULN	Eligibility	32
creatinine	CHEBI:16737	6-16
LVEF 50% by MUGA scan or echocardiography	Eligibility	33
Not pregnant or nursing	Eligibility	34
Negative pregnancy test	Eligibility	35
Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment	Eligibility	36
Exclusion criteria:	Eligibility	37
Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer	Eligibility	38
cancer	DOID:162	9-15
cancer	DOID:162	161-167
peripheral	HP:0030646	71-81
breast cancer	DOID:1612	154-167
Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study	Eligibility	39
severe	HP:0012828	35-41
disease	DOID:4,OGMS:0000031	70-77
Clinically significant cardiovascular disease within the past 6 months including any of the following:	Eligibility	40
disease	DOID:4,OGMS:0000031	38-45
Unstable angina	Eligibility	41
Congestive heart failure	Eligibility	42
congestive heart failure	HP:0001635,DOID:6000	0-24
Uncontrolled hypertension (i.e., blood pressure >150/90 mm Hg)	Eligibility	43
hypertension	HP:0000822,DOID:10763	13-25
blood	UBERON:0000178	33-38
Myocardial infarction	Eligibility	44
myocardial infarction	HP:0001658,DOID:5844	0-21
Cerebral vascular accidents	Eligibility	45
Known prior severe hypersensitivity reactions to agents containing Cremophor EL	Eligibility	46
severe	HP:0012828	12-18
hypersensitivity	GO:0002524,DOID:1205	19-35
Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule	Eligibility	47
condition	PDRO:0000129	73-82
Patients deprived of liberty or placed under the authority of a tutor	Eligibility	48
PRIOR CONCURRENT THERAPY:	Eligibility	49
At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered	Eligibility	50
surgery	OAE:0000067	35-42
breast	UBERON:0000310	54-60
At least 3 weeks since prior major surgery and adequately recovered	Eligibility	51
surgery	OAE:0000067	35-42
No prior chemotherapy, hormonal therapy, or radiotherapy	Eligibility	52
radiotherapy	OAE:0000235	44-56
More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:	Eligibility	53
Amiodarone	Eligibility	54
amiodarone	CHEBI:2663	0-10
Clarithromycin	Eligibility	55
clarithromycin	CHEBI:3732	0-14
Amprenavir	Eligibility	56
amprenavir	CHEBI:40050	0-10
Delavirdine	Eligibility	57
delavirdine	CHEBI:119573	0-11
Voriconazole	Eligibility	58
voriconazole	CHEBI:10023	0-12
Erythromycin	Eligibility	59
erythromycin	CHEBI:42355	0-12
Fluconazole	Eligibility	60
fluconazole	CHEBI:46081	0-11
Itraconazole	Eligibility	61
itraconazole	CHEBI:6076	0-12
Ketoconazole	Eligibility	62
ketoconazole	CHEBI:47519,BAO:0000796	0-12
Indinavir	Eligibility	63
indinavir	CHEBI:44032	0-9
Nelfinavir	Eligibility	64
nelfinavir	CHEBI:7496	0-10
Ritonavir	Eligibility	65
ritonavir	CHEBI:45409	0-9
Saquinavir	Eligibility	66
saquinavir	CHEBI:63621	0-10
No concurrent participation in another therapeutic trial involving an experimental drug	Eligibility	67
drug	CHEBI:23888	83-87
Outcome Measurement:	Results	0
Percentage of Participants With Disease-free Survival (DFS)	Results	1
DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first	Results	2
breast cancer	DOID:1612	81-94
breast cancer	DOID:1612	170-183
death	OAE:0000632	187-192
Time frame: At 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Docetaxel	Results	5
Arm/Group Description: 3 cycles of FEC100 (F and C, each at 500 mg/m , E 100 mg/m , every 3 weeks) followed by 3 cycles of D (100 mg/m  every 3 weeks)	Results	6
f	UO:0000195	33-34
f	UO:0000195	35-36
f	UO:0000195	43-44
f	UO:0000195	99-100
f	UO:0000195	121-122
Cyclophosphamide: 500 mg/m  every 3 weeks Docetaxel: 100 mg/m  every 3 weeks Epirubicin hydrochloride: 100 mg/m  every 3 weeks Fluorouracil: 500 mg/m  every 3 weeks	Results	7
cyclophosphamide	CHEBI:4026	0-16
hydrochloride	CHEBI:36807	88-101
Overall Number of Participants Analyzed: 398	Results	8
Measure Type: Number	Results	9
Unit of Measure: Percentage of participants  78.97        (74.53 to 82.73)	Results	10
Results 2:	Results	11
Arm/Group Title: Ixabepilone	Results	12
ixabepilone	CHEBI:63605	17-28
Arm/Group Description: 3 cycles of FEC100 (F and C, each at 500 mg/m , E 100 mg/m , every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m  every 3 weeks);	Results	13
f	UO:0000195	33-34
f	UO:0000195	35-36
f	UO:0000195	43-44
f	UO:0000195	99-100
f	UO:0000195	121-122
ixabepilone	CHEBI:63605	123-134
Cyclophosphamide: 500 mg/m  every 3 weeks Epirubicin hydrochloride: 100 mg/m  every 3 weeks Fluorouracil: 500 mg/m  every 3 weeks Ixabepilone: 40 mg/m  every 3 weeks	Results	14
cyclophosphamide	CHEBI:4026	0-16
hydrochloride	CHEBI:36807	53-66
ixabepilone	CHEBI:63605	130-141
Overall Number of Participants Analyzed: 364	Results	15
Measure Type: Number	Results	16
Unit of Measure: Percentage of participants  83.37        (79.06 to 86.87)	Results	17
Adverse Events 1:	Adverse Events	0
Total: 207/398 (52.01%)	Adverse Events	1
Anemia 1/398 (0.25%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Aplasia bone marrow 1/398 (0.25%)	Adverse Events	3
bone marrow	UBERON:0002371	8-19
Febrile aplasia 1/398 (0.25%)	Adverse Events	4
Febrile neutropenia 56/398 (14.07%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	8-19
Lymphocele 0/398 (0.00%)	Adverse Events	6
lymphocele	DOID:4347	0-10
Neutropenia 141/398 (35.43%)	Adverse Events	7
neutropenia	HP:0001875,DOID:1227	0-11
Auricular fibrillation 1/398 (0.25%)	Adverse Events	8
Non ST segment elevation acute coronary syndrome 0/398 (0.00%)	Adverse Events	9
st segment elevation	HP:0012251	4-24
acute coronary syndrome	HP:0033678	25-48
Tachycardia 1/398 (0.25%)	Adverse Events	10
tachycardia	HP:0001649	0-11
Ear disorder 0/398 (0.00%)	Adverse Events	11
ear	UBERON:0001690	0-3
disorder	OGMS:0000045	4-12
Adverse Events 2:	Adverse Events	12
Total: 158/364 (43.41%)	Adverse Events	13
Anemia 2/364 (0.55%)	Adverse Events	14
anemia	HP:0001903,DOID:2355	0-6
Aplasia bone marrow 1/364 (0.27%)	Adverse Events	15
bone marrow	UBERON:0002371	8-19
Febrile aplasia 4/364 (1.10%)	Adverse Events	16
Febrile neutropenia 27/364 (7.42%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	8-19
Lymphocele 1/364 (0.27%)	Adverse Events	18
lymphocele	DOID:4347	0-10
Neutropenia 95/364 (26.10%)	Adverse Events	19
neutropenia	HP:0001875,DOID:1227	0-11
Auricular fibrillation 0/364 (0.00%)	Adverse Events	20
Non ST segment elevation acute coronary syndrome 1/364 (0.27%)	Adverse Events	21
st segment elevation	HP:0012251	4-24
acute coronary syndrome	HP:0033678	25-48
Tachycardia 1/364 (0.27%)	Adverse Events	22
tachycardia	HP:0001649	0-11
Ear disorder 1/364 (0.27%)	Adverse Events	23
ear	UBERON:0001690	0-3
disorder	OGMS:0000045	4-12
